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Abstract
Sickle cell disease (SCD) is an autosomal recessive genetic condition that alters the shape and 
function of the hemoglobin molecule in red blood cells. While the overall survival rate among 
children with SCD has improved in recent years, pediatric rates of hospitalization, ED use, and 
mortality from complications of SCD remain high. Among patients ages 18 and older, hospital 
admission and ED usage are even greater—and the median age at death of people with SCD is 
considerably lower than that of the general population. Nurses who care for patients with SCD 
have an opportunity to improve health outcomes and quality of life for these patients by 
recognizing the major SCD-associated complications and providing patients and their caregivers 
with appropriate educational information. The authors discuss the genetic, hematologic, and 
clinical features of SCD and describe the major associated health complications. In addition, they 
review the nursing implications of each complication and provide online links to resources for 
clinicians, patients, and caregivers.
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Sickle cell disease (SCD) is an autosomal recessive genetic condition that alters the shape 
and function of the hemoglobin (Hb) molecule, causing red blood cells to take on the shape 
of a sickle (or crescent) (see Figure 1). The sickled blood cells break down prematurely, 
potentially producing anemia. Since they are rigid, they may become trapped in small blood 
vessels, triggering acute painful events, depriving tissues of oxygen-rich blood, and 
damaging organs, most notably, the spleen. Splenic injury greatly increases the risk of death 
from infection at a young age.
Millions of people throughout the world have SCD, most frequently those of African, South 
or Central American, Caribbean, Mediterranean, Indian, or Saudi Arabian descent. In the 
United States, it is the most common inherited blood disorder, affecting more than 100,000 
people, approximately 90% of whom are black and 10% of whom are Hispanic.1 (The 
number of non-black or non-Hispanic SCD patients is too low to estimate based on currently 
available data.) Of the four primary SCD genotypes, HbSS and HbSβ0-thalassemia tend to 
be the most clinically severe forms of the disease and are collectively termed sickle cell 
anemia (SCA). Generally, HbSC and HbSβ+-thalassemia are the more clinically benign 
forms, though severity varies among patients, and even patients with these typically milder 
forms of SCD commonly experience acute painful events and such serious complications as 
acute chest syndrome (ACS), silent cerebral infarction (SCI), avascular necrosis (AVN), 
priapism, and kidney failure throughout life.2–6
In 1987, the National Institutes of Health (NIH) convened a Consensus Development 
Conference on Newborn Screening for Sickle Cell Disease and Other Hemoglobinopathies, 
which recommended that all newborns in the United States be screened for SCD.7 It was not 
until 2006, however, that all 50 states and the District of Columbia had fully adopted the 
recommendation.8 Now, the identification of SCD in newborns enables physicians to initiate 
prophylactic penicillin and early vaccination against Streptococcus pneumoniae in order to 
prevent related infection or death, and provides family members an opportunity to learn how 
to reduce the child’s risk of potential SCD-related complications, to consider the 
implications of the child’s condition for their own and the child’s future family planning, 
and to seek evidence-based care for the child from health care professionals with an 
expertise in SCD. A 2010 study of the Dallas Newborn Cohort, which includes children who 
were diagnosed with SCD at birth (through newborn screening) and received ongoing care at 
a Dallas-based, tertiary SCD clinic from 1983 forward, found that the overall survival rate at 
age 18 was nearly 94% among children with SCA (up from 86% in 2004) and 99% among 
those with the less severe HbSC or HbSβ+-thalassemia (up from 97% in 2004). ACS and 
multisystem organ failure had replaced bacterial sepsis among these children as the leading 
causes of death.9
Despite increased survival among pediatric patients with SCD, hospitalization and ED usage 
rates are estimated to be seven to 30 and two to six times higher, respectively, than those of 
same-age cohorts without the disease.10 ED visits, hospital admissions, and hospital 
readmissions are even more frequent among 18-to-30-year-olds with SCD than among 
children or adults in middle or older age.11 The median age at death among patients with 
SCD is considerably lower than that of the general population: for men and women with 
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SCA, 42 and 48 years, respectively; for men and women with HbSC, 60 and 68 years, 
respectively.12
Two of the greatest challenges faced by clinicians caring for patients with SCD are the lack 
of evidence- based guidelines, owing to the paucity of data from large, randomized 
controlled trials involving SCD patients, and the underuse of the few recognized disease-
modifying therapies.13 Since, in the United States, SCD affects primarily black and Hispanic 
patients, it’s been suggested that “conscious or unconscious racial bias” has limited the 
availability of resources for research, as well as for the delivery and improvement of care.14 
An evidence-based report on the management of SCD, supported by the NIH and published 
by the National Heart, Lung, and Blood Institute (NHLBI), identified only seven areas in 
which strong recommendations based on high-quality evidence could be made.13, 15 (See 
NHLBI Expert Panel Recommendations for Managing Sickle Cell Disease.13, 15) The other 
recommendations are based on observation or low-quality evidence. This article reviews the 
major health complications faced by patients with SCD, discusses the nursing actions 
relevant to each, and provides a summary of these for quick reference (see Table 1). It also 
lists online links to several resources for clinicians, patients, and patient caregivers (see 
Sickle Cell Disease Clinical Care Resources), as well as little-known facts about SCD (see 
Facts About Sickle Cell Disease5, 9, 10, 16–19).
ACUTE PAIN
An acute vasoocclusive episode (VOE) is a new onset of severe pain that persists for at least 
four hours for which there is no explanation other than vasoocclusion. VOEs are the primary 
source of acute pain requiring medical attention in SCD, and they account for most acute 
pain episodes experienced by patients with this condition. VOEs can be treated with 
parenteral opioids, ketorolac, or other nonsteroidal antiinflammatory drugs. As patients grow 
older and learn strategies for alleviating the pain of VOEs, they often manage these episodes 
at home, but VOEs are the most common manifestation of SCD and the most common SCD-
related ED diagnosis.16 In a 2013 follow-up analysis of 264 adult patients with SCA in the 
Bethesda Sickle Cell Cohort study, approximately 40% reported no hospitalizations or ED 
treatments for VOEs within the past year, whereas 22% reported five or more 
hospitalizations or ED visits within that period, underscoring the tremendous variability of 
VOE severity that occurs in SCA.20
The clinical management of VOEs focuses on rapid pain assessment and administration of 
appropriate analgesics. Infants and toddlers often present with dactylitis, or pain and 
swelling from infarctions in the hands and feet; these may be the first SCD-related 
complications they experience (see Figure 2).21 Other common locations for VOE pain in 
patients of all ages include the chest, abdomen, back, and long bones. SCD genotype, older 
age, higher hematocrit levels, and lower fetal Hb levels are risk factors for VOE.12 Patients 
may have specific triggers for pain, such as extremes in temperature, dehydration, menstrual 
cycle changes, alcohol, or stress, but the majority of painful episodes have no identifiable 
cause. The effects of VOEs extend beyond the episodes themselves. Acute multisystem 
organ failure and death have also been reported during VOEs.22, 23 And patients with more 
frequent VOEs are shown to have a younger age at death.20
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Nursing implications.
A nurse’s comprehensive pain assessment, noting location, intensity, and duration of the 
pain episode, is invaluable. Nurses help patients identify what normally relieves the pain and 
whether the patient’s current pain is a typical VOE or suggests a different complication, such 
as ACS. As primary advocate for the patient, nurses can work with the prescribing clinician 
to ensure the patient receives adequate analgesia. Nurses can also work with patients to 
determine which nonpharmacologic adjunct therapies best relieve the pain. Most patients 
find heat application comforting; the application of ice is contraindicated in VOEs because 
vasoconstriction increases the pain by reducing oxygen delivery. Other nonpharmacologic 
therapies frequently used in SCD include cognitive behavioral therapy, biofeedback, prayer, 
relaxation techniques, acupuncture, hypnosis, herbal therapies, and megavitamins.24
After the pain has been relieved, nurses can work with patients to understand potential VOE 
triggers and how to avoid them and to ensure patients understand how to take the pain 
medicines prescribed to manage their pain. Nurses may also help patients understand the 
importance of hydration in preventing VOEs by increasing plasma volume and reducing 
blood viscosity. Unless contraindicated by conditions such as heart failure or renal disease, 
fluid intake may be encouraged. Finally, nurses can persuade patients, who may be reluctant 
to move because of pain, to walk and use the incentive spirometer every hour to prevent 
blood clots and pulmonary complications.
CHRONIC PAIN
Three subtypes of chronic pain have been identified in SCD25:
• chronic pain without contributing SCD complications, such as leg ulcers or AVN
• chronic pain with contributing SCD complications
• mixed presentation, when there is evidence of chronic pain from SCD 
complications but also apparently unrelated persistent pain
As with other types of chronic pain, SCD pain can cause patients to experience central 
sensitization, hyperalgesia, and altered opioid metabolism. Chronic pain not only causes 
discomfort but may also precipitate mood changes, emotional disturbance, and behavioral 
dysfunction, thereby affecting numerous facets of the patient’s life as well as the lives of 
family members, friends, and colleagues.26 In a six-month, prospective cohort study of 232 
patients with SCD who were age 16 or older, 29% experienced pain almost daily while 14% 
experienced pain on 5% or fewer days.27 This chronic pain was more frequent than VOEs 
and was often managed outside of a health care setting.
Nursing implications.
In addition to conducting a comprehensive pain assessment for acute VOEs, nurses can try 
to determine the type of chronic pain patients are experiencing. For example, a patient 
experiencing hip pain may require an orthopedic evaluation for AVN and possibly surgery. 
Nurses can also obtain a thorough medication history, including all opioid and nonopioid 
pain medications. Many patients with SCD require both short- and long-acting opioids and 
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may use these medications for sleep or anxiety in addition to pain. Nurses can help patients 
understand how to use long-term opioids most effectively and to encourage the use of 
nonpharmacologic interventions as adjunctive therapy.
AVASCULAR NECROSIS
When the bone’s blood supply is interrupted, bone tissue may die, a condition referred to as 
AVN. In people with SCD, AVN may result from VOEs in the bone’s microcirculation that 
cause thrombosis, infarction, and ultimately, necrosis.28 SCD severity and history of ACS 
may be risk factors for AVN,2 which can occur in people of all ages and has been seen in 
children as young as five years.29
Although the VOEs of SCD can occur in any organ, they are especially common in the bone 
marrow, particularly in the femoral or humeral head, where they can cause unilateral or 
bilateral AVN.28 In one study, the overall cumulative incidence of femoral head AVN was 
15% by age 30; the median age at diagnosis was 27, and nearly a quarter of the patients 
underwent hip replacement surgery at a median age of 36.2 Often, however, patients do not 
report the pain of AVN or are unable to obtain orthopedic follow-up. If undetected or 
untreated, AVN can cause permanent gait abnormalities and limb-length discrepancies, 
significantly impairing mobility.
Nursing implications.
The comprehensive pain assessment conducted by the nurse may provide the first clues that 
the patient has AVN. If AVN is suspected and an orthopedic consultation has not yet been 
recommended, the nurse should discuss assessment findings with the primary care provider. 
If the patient is diagnosed with AVN, the nurse can help the patient and family understand 
the condition and the various procedures that may be considered to alleviate related pain and 
disability.
PRIAPISM
Priapism is an undesired, persistent, and often painful erection that can lead to erectile 
dysfunction, substantially impairing quality of life. In boys and men with SCD, priapism is a 
common complication. Researchers have calculated that the actuarial probability of male 
patients with SCA experiencing priapism was nearly 13% by age 10, more than 50% by age 
15, and more than 89% by age 20.30
In a survey of 130 male patients with SCD being treated at one of five UK or Nigerian 
hospitals, a history of priapism was reported by 46 (35%) of respondents.3 Within this 
group, 24 (52%) reported a history of severe, prolonged priapism (lasting more than 24 
hours), which requires emergency treatment, and 33 (72%) reported a history of “stuttering” 
priapism—recurrent self-limited episodes, which are of much shorter duration. Stuttering 
episodes frequently heralded subsequent prolonged events, as only six of those reporting a 
history of severe priapism had no history of the stuttering type. In the group of 46 
respondents, the mean age of priapism onset was 15, with 75% reporting their first episode 
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before the age of 20 and 25% reporting a first episode before the age of 10. Sleep, sexual 
activity, and fever were frequent precipitating factors.3
Nursing implications.
Prevention is key but is hindered by a lack of knowledge and awareness of the complication. 
In a survey of patients with SCA ages five to 20, only 7% of the men who had not 
experienced priapism were aware of what it was and knew it was a potential complication of 
SCA.30 Patient teaching can include the use of analgesia, hydration, exercise, voiding, and 
warm baths to help prevent episodes.
Priapism can be an embarrassing problem for men with SCD, which may make it a difficult 
topic to discuss. Nurses may approach the discussion with an educational focus, providing 
answers to questions the patient may be afraid to ask. It’s important for patients with SCD to 
be knowledgeable about the condition, since it has potentially devastating sequelae. Nurses 
can emphasize the importance of reporting recurrent events and seeking medical attention 
for prolonged episodes within four hours of onset.
ACUTE CHEST SYNDROME
ACS was the leading cause of death in the Dallas Newborn Cohort of patients with SCD9 
and one of the most frequent causes of hospitalization in SCD.5 ACS is characterized by 
pleuritic chest pain, fever, rales on auscultation, and pulmonary infiltrates on chest X-ray.5 It 
can resemble other acute respiratory illnesses, including pneumonia, asthma exacerbation, or 
bronchiolitis.
Patient age affects presentation, etiology, and severity of ACS. Incidence is highest in 
children ages two to four years,5 but severity tends to be higher in adults, in whom studies 
have found mortality rates to be up to four times higher than in children.31 Children are 
more likely to present with wheezing, fever, and cough, whereas adults more often present 
with dyspnea, pain (commonly in the chest, ribs, sternum, arms, or legs), productive cough, 
and hemoptysis. ACS frequently occurs during hospitalization for VOE and following 
surgery.31, 32 In many cases, a cause is not evident or easily discernible. However, the most 
common etiologies are infection, followed by fat emboli from infarcted bone marrow. 
Following onset of symptoms, ACS can rapidly progress to respiratory failure, acute 
respiratory distress syndrome, or multisystem organ failure.
All patients with ACS should be hospitalized.15 Analgesia should be sufficient to reduce 
respiratory splinting and hypoventilation without causing atelectasis.33 Guidelines on the 
clinical management of ACS were published in 2015.18 Among the recommendations in the 
guidelines are aggressive incentive spirometry (10 maximum inspirations) every two hours 
while the patient is awake to prevent atelectasis and the development of ACS during 
hospitalization for VOE.18, 19 Although iv fluid administration is frequently a component of 
VOE management, excessive fluids can cause pulmonary edema and precipitate ACS.18
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Nursing implications.
Nurses can reduce the incidence of ACS by encouraging use of the incentive spirometer. 
Nurses can teach patients and family members the importance of appropriate use of the 
incentive spirometer and remain alert for subtle changes in respiratory status, such as 
increased work of breathing, decreased oxygen saturation, and new symptoms of cough or 
shortness of breath. Any change in respiratory status should be reported promptly to the 
primary care provider.
STROKE
Children and adults with SCD are at risk for cerebrovascular accidents such as ischemic 
stroke, hemorrhagic stroke, and silent stroke, also known as SCI. Analysis of clinical data on 
4,082 SCD patients in the Cooperative Study of Sickle Cell Disease (CSSCD) provided the 
following prevalence estimates for cerebrovascular accidents in patients whose SCD 
genotype could be confirmed34:
• HbSS, 4.01%
• HbSβ0-thalassemia, 2.43%
• HbSβ+-thalassemia, 1.29%
• HbSC, 0.84%
SCIs,
the most common strokes in children with SCD, are small infarctions detectable only by 
magnetic resonance imaging (MRI). Children with SCI typically present with no acute 
neurologic signs or symptoms. However, any child with SCD who presents with progressive 
neurocognitive deficits should have MRI screening for SCI because, though SCI most 
commonly occurs in SCA (before age six in approximately 27% of these children and before 
age 14 in approximately 37%), it also occurs in 3% to 38% of patients with HbSβ+-
thalassemia and in 5% to 31% of patients with HbSC.6, 35 Risk factors for SCI include low 
Hb levels, elevated systolic blood pressure, and male sex.6
Nursing implications.—Nurses should maintain a high index of suspicion for SCI in 
patients with SCD who have neurologic signs or symptoms. Any acute changes in 
neurologic symptoms, including altered mental status during a hospitalization, should be 
immediately reported to the patient’s primary care provider. Parents should be advised that 
poor academic performance is a red flag for potential neurocognitive deficits, possibly 
resulting from SCIs, and should be discussed with the child’s health care team.
Ischemic stroke is common in both young children and adults with SCD. The CSSCD 
found that among patients with the HbSS genotype, in whom all types of cerebrovascular 
accidents are more prevalent, incidence of ischemic stroke is highest in children ages two to 
nine years.34 In addition to having the HbSS genotype, risk factors for ischemic stroke 
include recent or recurrent ACS, elevated systolic blood pressure, low Hb level, prior 
transient ischemic attacks, and history of meningitis.
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Transcranial Doppler (TCD) ultrasound.—Prior to a first stroke, cerebral blood flow 
velocity may be elevated in children secondary to intracranial arterial stenosis.36 Ischemia 
may also occur because the narrowing of the vessel reduces the amount of blood that can 
flow through to the tissues. Elevated blood flow velocity can be measured by noninvasive 
TCD ultrasound. Positive TCD screens may warrant blood transfusion or hydroxyurea to 
reduce blood flow velocity and prevent stroke.37, 38 The NHLBI recommends annual TCD 
screening of children with SCA, starting at age two and continuing through age 16, with 
referral to a specialist when results fall outside the normal range.15
Nursing implications.—Nurses should reinforce with parents the need to seek care for 
any emerging neurologic symptoms in their children with SCD and teach them the 
importance of routine TCD screening of children with SCA.
Hemorrhagic stroke.
The CSSCD found that hemorrhagic strokes occur most commonly in young adults ages 20 
to 29 and were associated with a mortality rate of 24% overall and 26% in patients with the 
HbSS genotype.34 Hemorrhagic strokes, which are associated with weakened cerebral blood 
vessels and aneurysms, usually occur suddenly, with symptoms of severe headache; 
vomiting; seizures; and changes in alertness, sensation, and language.39 Risk factors for 
hemorrhagic stroke include low Hb level, high leukocyte count, and history of ACS.34, 39
SPLENIC COMPLICATIONS
The spleen is one of the first organs affected by SCD. In children with SCA, hyposplenism, 
a physiological reduction in spleen function, is usually evident within the first year of life.40 
Splenic dysfunction is believed to stem from vasoocclusion of the organ by sickled 
erythrocytes and subsequent ischemia, fibrosis, and progressive atrophy of the organ. The 
spleen is a major filter of the blood and plays an important role in immune defense as well as 
in vascular and blood homeostasis by removing senescent or altered red blood cells, 
microorganisms, and blood-borne antigens. Splenic damage puts patients at risk for immune 
dysfunction, vascular narrowing and occlusion, and severe bacterial infection. People with 
SCD remain at high risk for infection and sepsis throughout life.
Nursing implications.
Patient and family teaching should emphasize the importance of receiving all recommended 
immunizations as well as annual influenza vaccines. Parents should be taught the importance 
of recognizing fever early and notifying their child’s primary care provider. Elevated 
temperatures in hospitalized children should be immediately reported to the primary care 
provider because a sepsis evaluation may be necessary.
Acute splenic sequestration crisis.
The splenic damage seen in patients with SCD is typically silent and progressive, but it 
becomes clinically apparent in acute splenic sequestration crisis (ASSC), a life-threatening 
complication involving rapid accumulation of sickled erythrocytes within the spleen.41 
ASSC is defined as sudden splenomegaly, a reduction in Hb concentration of at least 2 g/dL, 
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and a normal or elevated basal reticulocyte count. The spleen enlarges within a period of 
hours, trapping a large portion of circulating erythrocytes and acutely worsening the anemia 
and circulatory failure. Symptoms include abdominal pain and distension, pallor, 
tachycardia, hypotension, and lethargy. Hypovolemic shock and death from cardiovascular 
collapse can occur within hours if untreated. In children with SCD, ASSC is one of the 
earliest life-threatening complications and may be the first clinical manifestation of the 
disease, occurring at a median age of 1.4 years, and as early as several weeks of age.42 More 
than 12% of children with SCA experience ASSC, and 67% of those go on to have at least 
one more occurrence. In patients with HbSC, sequestration may occur in early and late adult 
hood.43
INFECTION AND SEPSIS
All SCD genotypes put patients at increased risk for severe infection—particularly invasive 
bacterial infection—throughout life. This increased susceptibility is largely due to splenic 
and immune dysfunction. Young children with SCA in particular are at elevated risk for 
pneumonia, septicemia, and men- ingitis.44, 45 Incidence of these infections is lower in 
patients with HbSC and HbSβ+-thalassemia genotypes because splenic function is typically 
normal or only minimally impaired in infancy. The risk, however, is present in later 
childhood and adulthood.46 Other infections are also common in SCD. VOE of the bone and 
subsequent necrosis predisposes patients to osteomyelitis.47 Parvovirus B19, which is often 
asymptomatic in those without SCD, can trigger aplastic crisis and life-threatening anemia 
in people with SCD.48 Risk of catheter-related infections is also higher in SCD. Infection is 
a common precipitant of VOE and the most common cause of ACS.32 Because of increased 
risks of infection, including infection with penicillin-resistant organisms, and incomplete 
vaccination in patients with SCD, any fever higher than 101.3°F (38.5°C) is considered a 
medical emergency requiring further evaluation.15
Nursing implications.
Nurses should closely monitor vital sign trends, particularly temperature, in patients with 
SCD. Elevations in fever should be reported to the primary care provider immediately. 
Nurses should also teach patients and parents the importance of monitoring temperature and 
the need for age-appropriate immunizations.
ORGAN FAILURE
Renal disease.
It’s estimated that 16% to 18% of overall mortality in SCD is related to renal complications.
49
 The most common renal complication in SCD is hyposthenuria (the inability to 
concentrate urine), which can lead to urinary frequency, enuresis, and increased risk of 
intravascular volume depletion.50 Compared with the general U.S. population, patients with 
SCD are two to three times as likely to develop acute renal failure or chronic kidney disease.
51
Adults with serum creatinine elevations above 1 mg/dL and children with elevations above 
0.7 mg/dL are classified as having renal impairment and should receive nephrology 
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consultation.15 Microalbuminuria is the first manifestation of chronic kidney disease, and all 
patients with SCD should be screened for proteinuria annually beginning at age 10.15 Risk 
factors for both acute renal failure and chronic kidney disease include the following51:
• advanced age
• male sex
• proteinuria
• diabetes
• hypertension
• chronic heart disease
• history of blood transfusion
Additional risk factors for chronic kidney disease include hypertension and dyslipidemia.51
Nursing implications.—Nurses should be aware of the renal status of all patients with 
SCD and pay careful attention to kidney disease risk factors throughout hospitalization. 
Nurses should also maintain a high index of suspicion for proteinuria and decreased urine 
output, bearing in mind the patient’s dialysis schedule. When patients are hospitalized, all 
health care team members need to work together to minimize disruptions to this schedule.
Multisystem organ failure
in SCD is usually characterized by dysfunction of at least two or three major organ systems 
and often develops after several days of hospital treatment for a VOE, when pain is 
improving.22 Deterioration is typically rapid and associated with fever, nonfocal 
encephalopathy, and decreased Hb and platelet levels. Significant overlap between severe 
ACS due to fat emboli and multisystem organ failure has been noted. Multisystem organ 
failure is thought to result in part from diffuse microvascular occlusion and tissue ischemia.4
Nursing implications.—Multisystem organ failure may occur rapidly in any patient with 
SCD. It is of- ten signaled by changes in respiratory status or renal function. Nurses should 
consider any elevation in respiratory rate or reduction in oxygen saturation to be a potential 
early sign of ACS and report such signs to the patient’s primary care provider. Renal 
function and iv fluid administration should also be monitored, especially in patients with a 
history of renal failure.
PSYCHOSOCIAL COMPLICATIONS
People with SCD suffer from a high incidence of social and behavioral health complications. 
Anxiety and depression have been reported to be as high as 7% and 28%, respectively, in 
these patients.52 Social and behavioral health complications can occur throughout life.
Severe disease may cause young children to miss school, limit college and job opportunities 
for young adults, and reduce career opportunities for older adults. Such losses present 
significant financial challenges, often limiting access to health care, insurance, and 
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necessary medications. Interviews with 147 ED patients with SCD, conducted by social 
workers over a 14-month period, revealed that 27% and 17% of patients, respectively, 
experienced difficulties obtaining insurance coverage and meeting copay requirements for 
prescriptions.53 Other issues that may affect patients’ ability to manage SCD effectively 
include navigating the time and transportation challenges involved in seeing numerous 
health care specialists while trying to work and take care of family responsibilities. It is not 
uncommon for patients to need to see an ophthalmologist, orthopedic surgeon, or 
nephrologist in addition to a sickle cell specialist and primary care provider.
Nursing implications.
Nurses should assess patients, especially those with frequent ED visits and hospitalizations, 
for behavioral health complications to identify those who may benefit from social work, 
psychiatric, or case management referral. Patients should also be screened for depression, 
anxiety, and other social and behavioral determinants of health. When possible, nurses 
should refer patients with such complications to the social worker or case manager, who may 
be able to guide them in seeking extra support. A strong social support network is key to 
effective disease management and to a good quality of life in those with SCD.▼
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NHLBI Expert Panel Recommendations for Managing Sickle Cell 
Disease13, 15
• In children with conditional (170 to 199 cm/sec) or elevated (> 200 cm/sec) 
transcranial Doppler (TCD) screening results, refer to a specialist with 
expertise in chronic transfusion therapy aimed at preventing stroke.
• In children and adults with sickle cell disease (SCD) and a vasoocclusive 
crisis associated with severe pain, rapidly initiate treatment with parenteral 
opioids.
• Treat avascular necrosis with analgesics and consult physical therapy and 
orthopedics for assessment and follow-up.
• Treat adults with sickle cell anemia who have three or more sickle cell–
associated moderate-to-severe pain crises in a 12-month period with 
hydroxyurea.
• Regardless of clinical severity, to reduce SCD-related complications—such as 
pain, dactylitis, acute chest syndrome, or anemia—offer treatment with 
hydroxyurea to infants ages nine months or older, children, and adolescents 
who have sickle cell anemia.
• To ensure proper use of hydroxyurea and maximize benefits and safety, use an 
established prescribing and monitoring protocol.
• Use simple or exchange transfusion for children with TCD readings of > 200 
cm/sec.
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Facts About Sickle Cell Disease
• In the United States, the median age at death for men and women with sickle 
cell anemia is 42 and 48, respectively, and for men and women with HbSC, it 
is 60 and 68, respectively.17
• Among children with sickle cell disease (SCD), hospitalization and ED rates 
are estimated to be seven to 30 and two to six times higher, respectively, than 
those of same-age children without SCD.10
• Vasoocclusive episodes are the most common manifestation of SCD and the 
most common SCD-related ED diagnosis.16
• Aggressive incentive spirometry can reduce risk of acute chest syndrome,
18, 19
 the primary cause of death9 and one of the most frequent causes of 
hospitalization in both children and adults with SCD.5
• Strong social support is key to good disease management and quality of life. 
Patients lacking a support network may benefit from social work, psychiatric, 
or case management referral.
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Sickle Cell Disease Clinical Care Resources
American Society of Hematology
Pocket guides for clinicians can be downloaded or ordered, such as Management of 
Acute Complications of Sickle Cell Disease, Health Maintenance and Management of 
Chronic Complications of Sickle Cell Disease, and Hydroxyurea and Transfusion 
Therapy for the Treatment of Sickle Cell Disease. www.hematology.org/Clinicians/
Guidelines-Quality/Quick-Reference.aspx
Centers for Disease Control and Prevention
Materials and Multimedia on Sickle Cell Disease https://www.cdc.gov/ncbddd/sicklecell/
materials/index.html
National Heart, Lung, and Blood Institute
Evidence-Based Management of Sickle Cell Disease: Expert Panel Report, 2014 
www.nhlbi.nih.gov/health-topics/evidence-based-management-sickle-cell-disease
National Institute for Children’s Health Quality
On the Resources page, you can sign up for the Sickle Cell Disease Treatment 
Demonstration Program Compendium of Tools and Materials www.nichq.org/resource/
sickle-cell-disease-treatment-demonstration-program-compendium-tools-and-materials
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For five additional continuing nursing education activities related to sickle cell disease, 
go to www.nursingcenter.com/ce.
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Figure 1. 
Normal red blood cells are round and flexible and move easily through blood vessels. In 
sickle cell disease, abnormal hemoglobin causes red blood cells to become sickle (or 
crescent) shaped and rigid. The misshapen cells can easily become lodged in smaller blood 
vessels, depriving tissues of oxygen and triggering painful episodes. Illustration by Alila 
Medical Media.
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Figure 2. 
The hand of an infant with dactylitis—a painful swelling of the fingers or toes. Photo 
courtesy of Tom D. Thacher, MD.
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 a
dm
in
ist
ra
tio
n 
w
ith
 th
e 
pr
im
ar
y 
ca
re
 p
ro
v
id
er
,
 
an
d 
m
on
ito
r f
lu
id
 in
ta
ke
 a
n
d 
ur
in
ar
y 
ou
tp
ut
.
•
M
on
ito
r p
at
ie
nt
s f
or
 a
ny
 c
ha
ng
es
 in
 re
sp
ira
to
ry
 st
at
us
 a
nd
 re
po
rt 
ev
en
 m
in
or
 c
ha
ng
es
, s
uc
h 
as
 e
le
v
at
ed
 re
sp
ira
to
ry
 ra
te
 o
r d
ec
re
as
ed
 o
xy
ge
n 
sa
tu
ra
tio
n,
 to
 th
e 
pr
im
ar
y 
ca
re
 p
ro
v
id
er
,
 
as
 th
ey
 c
ou
ld
 b
e 
ea
rly
 si
gn
s o
f A
CS
.
•
W
o
rk
 w
ith
 o
th
er
 m
em
be
rs
 o
f t
he
 h
ea
lth
 c
ar
e 
te
am
 to
 m
in
im
iz
e 
di
sr
up
tio
ns
 to
 p
at
ie
nt
s’
 d
ia
ly
sis
 sc
he
du
le
.
Ps
yc
ho
so
ci
al
 c
om
pl
ic
at
io
ns
•
A
ss
es
s p
at
ie
nt
s, 
es
pe
ci
al
ly
 th
os
e 
w
ith
 fr
eq
ue
nt
 E
D
 v
isi
ts 
an
d 
ho
sp
ita
liz
at
io
ns
, f
or
 th
e 
pr
es
en
ce
 o
f p
sy
ch
os
oc
ia
l h
ea
lth
 c
om
pl
ic
at
io
ns
 to
 id
en
tif
y 
an
y 
w
ho
 
m
ay
 b
en
ef
it 
fro
m
 so
ci
al
 w
o
rk
, p
sy
ch
ia
tri
c,
 o
r c
as
e 
m
an
ag
em
en
t r
ef
er
ra
l.
A
CS
 =
 a
cu
te
 c
he
st 
sy
nd
ro
m
e;
 A
V
N
 =
 a
v
as
cu
la
r n
ec
ro
sis
; N
SA
ID
 =
 n
on
ste
ro
id
al
 a
nt
iin
fla
m
m
at
or
y 
dr
ug
; S
CA
 =
 si
ck
le
 c
el
l a
ne
m
ia
; S
CD
 =
 si
ck
le
 c
el
l d
ise
as
e;
 S
CI
 =
 si
le
nt
 c
er
eb
ra
l i
nf
ar
ct
io
n;
 T
CD
 =
 
tr
an
sc
ra
ni
al
 D
op
pl
er
; V
O
E 
= 
va
so
o
cc
lu
siv
e 
ep
iso
de
.
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